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Abstract 
Purpose: Downregulation of miR‑125b‑1 is associated with poor prognosis in breast cancer patients. In this work we 
investigated the effect of histone modifications on the regulation of this gene promoter.
Methods and results: We evaluated the enrichment of two histone modifications involved in gene repression, 
H3K9me3 and H3K27me3, on the miR‑125b‑1 promoter in two breast cancer cell lines, MCF7 (luminal A subtype) and 
MDA‑MB‑231 (triple‑negative subtype), compared to the non‑transformed breast cell line MCF10A. H3K27me3 and 
H3K9me3 were enriched in MCF7 and MDA‑MB‑231 cells, respectively. Next, we used an EZH2 inhibitor to examine 
the reactivation of miR‑125b‑1 in MCF7 cells and evaluated the transcriptional levels of pri‑miR‑125b‑1 and mature 
miR‑125b by qRT‑PCR. pri‑miRNA and mature miRNA transcripts were both increased after treatment of MCF7 cells 
with the EZH2 inhibitor, whereas no effect on miR‑125b‑1 expression levels was observed in MDA‑MB‑231 and 
MCF10A cells. We subsequently evaluated the effect of miR‑125b‑1 reactivation on the expression and protein levels 
of BAK1, a target of miR‑125b. We observed 60 and 70 % decreases in the expression and protein levels of BAK1, 
respectively, compared to cells that were not treated with the EZH2 inhibitor. We over‑expressed KDM4B/JMJD2B 
to reactivate this miRNA, resulting in a three‑fold increase in miR‑125b expression compared with the same cell line 
without KDM4B/JMJD2B over‑expression.
Conclusion: The miR‑125b‑1 is repressed by different epigenetic mechanisms depending on the breast cancer 
subtype and that miR‑125b‑1 reactivation specifically eliminates the effect of repressive histone modifications on the 
expression of an pro‑apoptotic target.
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Background
MicroRNAs (miRNAs) are short single-stranded RNAs 
that could regulate gene expression at the post-tran-
scriptional level. miRNAs are typically transcribed as 
primary transcripts (pri-miRNAs) that are subsequently 
matured in a multi-step biogenesis process to generate 
the functional form or mature miRNA (Lee and Dutta 
2009). Accumulating evidence indicates that miRNA 
deregulation is related to pathologies including cancer. 
Some miRNAs are associated with tumor suppressor or 
oncogene activity, depending on the downregulated tar-
get (Di Leva et al. 2014).
In particular, miR-125b-1 exhibits tumor suppressor 
activity in some types of cancer, including breast, ovar-
ian and bladder cancer (Banzhaf-Strathmann 2014). mir-
125b-1 may be involved in biological processes such as 
apoptosis, cell proliferation and cell migration because 
it regulates genes such as BAK1 (Zhou et  al. 2010), 
ERBB2 (Scott et al. 2007) and ETS1 (Zhang et al. 2011), 
respectively. In most breast cancer tumors, miR-125b-1 
downregulation is associated with a poor prognosis. 
miR-125b-1 can be repressed by DNA methylation in 
the promoter region (Zhang et al. 2011; Soto-Reyes et al. 
2012). However, the miR-125b-1 promoter is within a 
CpG island promoter with intermediate CpG content. 
Promoters with intermediate CpG content are typically 
regulated by DNA methylation and histone modifications 
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(Weber et al. 2007). Thus, we were interested in evaluat-
ing the relevance of repressive histone modifications in 
miR-125b-1 downregulation.
In this study, we evaluated repressive histone modi-
fications in the promoter regions of miR-125b-1 and 
the effect on the transcriptional regulation of this gene. 
Chromatin immunoprecipitation revealed H3K9me3 
and H3K27me3 histone modifications associated with 
gene repression in the miR-125b-1 promoter in breast 
cancer cell lines. These histone modifications were then 
removed by over-expressing KDM4B/JMJD2B to remove 
H3K9me3 (Fodor et al. 2006) or using an EZH2 inhibitor 
to remove H3K27me3 (McCabe et  al. 2012). Finally, we 
evaluated miR-125b-1 reactivation by quantitative real-
time PCR (qRT-PCR) and the effect on a target of this 
miRNA.
Methods
Human breast cell lines and treatment
The human breast cancer cell lines MCF7 and MDA-
MB-231 were cultured in DMEM/F12 supplemented 
with 10 % fetal bovine serum (GIBCO). MCF10A, a non-
transformed cell line, was cultured in DMEM/F12 (3:1) 
supplemented with 10  % fetal bovine serum (GIBCO), 
2  mM glutamine (GIBCO), 10  ng/mL EGFrh (Invitro-
gen), 120 mU/mL human recombinant insulin (Insulinex) 
and 1 µg/mL hydrocortisone (SIGMA).
To eliminate the H3K9me3 histone modification, 
MCF10A and MDA-MB-231 were transfected with a 
plasmid encoding KDM4B/JMJD2B-GFP (Fodor et  al. 
2006) using Lipofectamine LTX (Invitrogen). As a con-
trol, the same cell lines were transfected with empty plas-
mid. Plasmid-carrying cells were selected by cell sorting 
using a FACSAria III cytometer (BD). To eliminate the 
H3K27me3 histone modification, the breast cell lines 
were incubated with 200, 500, 1000 or 2000 nM GSK126 
for 4 days.
RNA isolation and qRT‑PCR expression analysis
Total RNA was isolated from cells using TRIzol rea-
gent (Invitrogen). pri-miR-125b-1 and pri-miR-125b-2 
expression levels were evaluated by qRT-PCR using 
SYBR Green (ThermoFisher Scientific). Mature miR-
125b expression levels were quantified by qRT-PCR 
using a TaqMan assay according to the manufacturer’s 
protocol (Applied Biosystems). One hundred nano-
grams of total RNA were reverse transcribed using spe-
cific stem-loop RT primers. Next, the products were 
amplified and detected by PCR with specific primers 
and TaqMan probes (miR-125b, Applied Biosystems). 
U6 snRNA served as an internal normalized reference. 
The amplification and detection of specific products 
were calculated by the 2−ΔΔCt method.
Western blot analysis
Cells were grown in 10-cm2 dishes and lysed using Cell 
Lysis Buffer (Cell Signaling) with protease inhibitor cock-
tail (Cell Signaling) and 100  µM PMSF (SIGMA). Pro-
tein samples were resolved on 12 % Tris–glycine gels and 
transferred to PVDF membranes. The membranes were 
then incubated with α-H3K27me3 (1:1000; Millipore, 
07-449), α-H3 (1:1000; SIGMA, H0164), α-BAK1 (Santa 
Cruz, sc-832) and α-GAPDH (Santa Cruz, sc-25778). 
After washing with TBS, the membranes were incubated 
with peroxidase-conjugated goat anti-rabbit antibody 
(1:20,000; Novus, NB7187) followed by chemilumines-
cence staining (Millipore).
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was 
performing using the OneDay ChIP kit (Diagenode) 
according to the manufacturer’s protocol. To immuno-
precipitate H3K9me3 and H3K27me3, we used 4 µg each 
of α-H3K9me3 (Abcam, ab-8898) and -H3K27me3 (Mil-
lipore, 07-449), respectively. The immunoprecipitated 
DNA was analyzed by PCR using primers specific for 
the miR-125b1 promoters. As positive ChIP controls, we 
used SOX-9 and MYT-1 promoters.
Statistical analysis
Data from at least three independent experiments are 
expressed as the mean ± standard deviation. Differences 
between groups were analyzed using Student’s t test. 
Data were considered significant at p < 0.05.
Results
miR‑125b‑1 is downregulated in breast cancer cell lines
miR-125b (mature miRNA) is transcribed from two dif-
ferent genes: miR-125b-1 (chromosome 11) and miR-
125b-2 (chromosome 21). However, the transcriptional 
activity of miR-125b-2 is low (Additional file  1: Fig.  1). 
Thus, most miR-125b is derived from the miR-125b-1 
gene. To determine miR-125b-1 expression levels, we 
evaluated pri-miRNA and mature miRNA levels in the 
breast cancer cell lines MCF7 and MDA-MB-231 by qRT-
PCR compared with the non-transformed breast cell line 
MCF10A. pri-miR-125b-1 levels in MCF7 and MDA-
MB-231 cells were reduced by 99 and 72 %, respectively, 
compared with MCF10A cells. However, mature miR-
125b levels were reduced only in MCF7 cells. In MDA-
MB-231 cells, mature miR-125b levels were increased by 
nearly threefold (Fig. 1). This increment of miR-125b in 
Page 3 of 7Cisneros‑Soberanis et al. SpringerPlus  (2016) 5:959 
MDA-MB-231 cells may be associated with the accumu-
lation of miRNA transcripts.
Histone modification marks in miR‑125b‑1 promoter 
regions
Two promoters are associated with miR-125b-1 tran-
scriptional regulation. The first is in a CpG island close 
to the miR-125b-1 sequence (Wang et al. 2013). This CpG 
island has an intermediate CpG content, and thus the 
transcriptional regulation of miR-125b-1 may be associ-
ated with DNA methylation and histone modifications 
(Weber et al. 2007; Marson et al. 2008). The second pro-
moter is 55 kb upstream from the miR-125b-1 sequence. 
This promoter, which may regulate the transcription of 
the miR-125b-1, let-7a-2 and miR-100 genes (Chien et al. 
2011), is not in a CpG island, and thus the regulation of 
these genes may be associated with histone modifications 
(Fig. 2).
To further investigate the repressive mechanism of 
miR-125b-1 in breast cancer cell lines, we evaluated 
two histone modifications involved in gene repression: 
H3K9me3 and H3K27me3. H3K9me3 and H3K27me3 
are associated with constitutive and facultative hetero-
chromatin, respectively. We observed enrichment of 
H3K9me3 in both promoters in MDA-MB-231 cells 
but not MCF7 and MCF10A cells (Fig.  2a). However, 
in MCF7 cells, we observed twofold enrichment of 
H3K27me3 compared with MCF10A cells. We did not 
observe this enrichment on miR-125b-1 promoters in 
MDA-MB-231 cells (Additional file 2: Fig. 2; Fig. 2b).
miR‑125b‑1 reactivation in MDA‑MB‑231 by KDM4B/
JMJD2B over‑expression
To determine the role of H3K9me3 in MDA-MB-231 
cells, we over-expressed KDM4B/JMJD2B to reduce 
global levels of H3K9me3 histone modification in 
MCF10A and MDA-MB-231 cells. We specifically 
selected transfected cells over-expressing KDM4B/
JMJD2B by cell sorting (Fig.  3a). Subsequent qRT-PCR 
analysis revealed a three-fold increase in miR-125b lev-
els in KDM4B/JMJD2B-transfected MDA-MB-231 cells 
compared with MDA-MB-231 cells transfected with 
empty vector. However, no significant differences in miR-
125b levels were observed between KDM4B/JMJD2B-
transfected MCF10A cells and empty vector-transfected 
MDA-MB-231 cells (Fig. 3b).
miR‑125b‑1 is reactivated by an EZH2 inhibitor in MCF7 
cells
To determine if H3K27me3 is responsible for miR-125b-1 
repression, we treated the breast cell lines with the EZH2 
inhibitor GSK126. GSK126 is more than 1000-fold selec-
tive for EZH2 versus 20 other human methyl transferases 
(McCabe et  al. 2012). To choose an effective GSK126 
concentration without altering other methyltransferases, 
we constructed a dose curve to determine the mini-
mum GSK126 concentration at which global H3K27me3 
was decreased. We estimated global H3K27me3 levels 
by Western blotting and determined that 1000  nM was 
the minimum effective GSK126 concentration to evalu-
ate miR-125b-1 reactivation in breast cancer cell lines 
Fig. 1 The miR‑125b‑1 precursor and mature transcript are downregulated in the MCF7 breast cancer cell line. We evaluated the expression levels 
of pri‑miR‑125b‑1 and mature miR‑125b in the MCF10A non‑transformed breast cell line and the two breast cancer cell lines MCF7 and MDA‑
MB‑231. *p > 0.001
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(Fig.  4a, b). Subsequent qRT-PCR analysis revealed that 
the expression levels of pri-miR-125b-1 (primary tran-
script) and miR-125b (mature transcript) were increased 
ninefold (Fig.  4c) and 16-fold (Fig.  4d), respectively, in 
MCF7 cells compared untreated MCF7 cells. Interest-
ingly, no changes in pri-miR-125b-1 (Fig. 4c) and mature 
miR-125b (Fig. 4d) transcription levels were observed in 
MDA-MD-231 and MCF10A cells. Hence, we conclude 
that H3K27me3 is responsible for miR-125b-1 repression 
in MCF7 cells.
miR‑125b‑1 reactivation affects the expression levels 
of BAK1
mir-125b is involved in biological processes such as 
apoptosis, cell proliferation and cell migration-regulating 
genes such as BAK1 (Zhou et  al. 2010), ERBB2 (Scott 
et al. 2007) and ETS1 (Zhang et al. 2011), respectively. We 
therefore sought to evaluate the effects of miR-125b-1 
reactivation on the expression and protein levels of its 
targets. Using the ENCODE database, we evaluated the 
presence of H3K27me3 on some miR-125b target gene 
promoters in the MCF7 cell line (Additional file 3: Fig. 3). 
This histone modification was absent only in BAK1 
(Fig.  5a). This analysis is important because GSK126 
treatment of MCF7 cells may alter the expression and 
protein levels of target genes via an miR-125b-independ-
ent mechanism.
We therefore evaluated BAK1 transcription levels in 
MCF7 cells treated with and without GSK126 by qRT-
PCR. We observed a 71 % reduction in BAK1 expression 
levels in MCF7 cells treated with GSK126 (Fig. 5b). Next, 
we determined the proteins levels of BAK1 by Western 
blotting. We observed a 53 % reduction in BAK1 protein 
levels in MCF7 cells treated with GSK126 (Fig. 5c, d). We 
therefore conclude that miR-125b-1 reactivation affects 
the expression and protein levels of BAK1, an miR-125b 
target.
Discussion
miR-125b is an miRNA that may be involved indirectly 
in biological processes such as apoptosis, cell prolif-
eration and cell migration (Banzhaf-Strathmann 2014). 
miR-125b-1 downregulation has been associated with 
increased cell proliferation (Scott et  al. 2007), metasta-
sis (Zhang et  al. 2011) and drug resistance (Zhou et  al. 
2010; Wang et  al. 2013; Vilquin et  al. 2015) in breast 
cancer. miR-125b-1 repression has been associated with 
DNA methylation on its promoter region (Zhang et  al. 
2011; Soto-Reyes et al. 2012). However, in this study, we 
were interested in evaluating the relationship between 
Fig. 2 H3K9me3 and H3K27me3 are enriched on miR‑125b‑1 promoters in MDA‑MB‑231 and MCF7 breast cancer cells, respectively. To determine 
which histone modification was involved in miR‑125b‑1 repression, we evaluated H3K9me3 (a) and H3K27me3 (b) expression in the promoter 
regions by chromatin immunoprecipitation
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Fig. 3 JMJD2B over‑expression reactivates miR‑125b in MDA‑MB‑231 breast cancer cells. To determine if H3K9me3 is involved in miR‑125b‑1 
repression, we over‑expressed JMJD2B in MCF10A and MDA‑MB‑231 breast cells and then selected cells over‑expressing JMJD2B by sorting (a). 
After the selection, we evaluated the expression levels of miR‑125b (b)
Fig. 4 An inhibitor of EZH2 reactivates miR‑125b‑1 in MCF7 breast cancer cells. To determine the dose of GSK126 that reduces H3K27me3 levels, 
we treated the breast cell lines with different GSK126 concentrations and performed Western blot analysis (a). b Densitometric analysis of triplicate 
Western blots. We chose the 1000‑nM dose to evaluate pri‑miR‑125b‑1 (c) and mature miR‑125b expression levels (d)
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miR-125b-1 repression and repressive histone modi-
fications such as H3K9me3 and H3K27me3. As a study 
model, we used two breast cancer cell lines, MCF7 (lumi-
nal A subtype) and MDA-MB-231 (triple-negative sub-
type), and the non-transformed breast cell line MCF10A.
We detected H3K9me3 and H3K27me3 in the miR-
125b-1 promoter region in MDA-MB-231 and MCF7 
cells, respectively. These histone modifications were 
mutually exclusive and did not coexist. These repressive 
histone modifications are related to different silencing 
mechanisms. The H3K9me3 repressive histone modifica-
tion is associated with constitutive heterochromatin. His-
tone methyltransferases, such as G9a and SUV39H1, are 
involved in “writing this mark”. H3K9me3 is commonly 
localized in repeat regions but is not usually observed 
in gene-rich regions (Kim 2012). Thus, the presence of 
H3K9me3 on the miR-125b-1 promoter in MDA-MB-231 
cells is unusual. However, the presence of this histone 
modification is important in miR-125b-1 transcriptional 
regulation because when removal of the H3K9me3 mark 
reactivated this miRNA (Fig. 3).
By contrast, the H3K27me3 repressive histone modifi-
cation is associated with facultative heterochromatin and 
the presence of the Polycomb complex. This repressive 
histone modification is generally localized in gene-rich 
regions (Kim 2012; Chase and Cross 2011). In breast can-
cer tumors, H3K27me3 has been related to clinical stage 
and estrogen-receptor positive tumors (Healey et  al. 
2014). Some groups have reported an increase in the 
transcriptional levels of EZH2 (a H3K27 histone methyl-
transferase) in the luminal breast cancer subtype (Healey 
et al. 2014), and an association between increased EZH2 
activity and poor prognosis has been reported (Jene-Sanz 
et al. 2013; Holm et al. 2012). These analyses are relevant 
to our work because miR-125b-1 is an EZH2 target in the 
luminal breast cancer cell line MCF7. miR-125b-1 repres-
sion by EZH2 may be involved in drug resistance because 
miR-125b can downregulate BAK1, an anti-apoptosis 
gene (Zhou et al. 2010). We demonstrated that the reac-
tivation of miR-125b-1 decreases BAK1 expression 
and protein levels (Figs. 4, 5). This result suggests that a 
decrease in BAK1 may increase the sensitivity of cells to 
Taxol treatment (Zhou et al. 2010).
We conclude that miR-125b-1 is transcriptionally reg-
ulated by histone modifications such as H3K9me3 and 
H3K27me3, depending on the breast cancer cell subtype. 
In the luminal breast cancer cell line, we demonstrated 
that the reactivation of this miRNA affects the expres-
sion and protein levels of BAK1, a target involved in 
anti-apoptosis.
Fig. 5 Elevated levels of miR‑125b‑1 affect the expression levels of BAK1. The target BAK1 was selected based on an evaluation of H3K27me3 
enrichment in MCF7 cells by ENCODE (a). Next, we evaluated BAK1 expression levels by qRT‑PCR (b). Finally, we determined protein levels by West‑
ern blotting (c, d). n = 3 *p > 0.05
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